Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.
暂无分享，去创建一个
G. Abou-Alfa | S. Clarke | E. Hitre | K. Weiss | J. Valle | I. Borbath | D. Oh | C. Louvet | M. Javle | Y. Ye | J. Spratlin | S. Moran | C. Berman | T. M. Mercadé | M. Howland | T. Cho